Last reviewed · How we verify

Migraine with aura — Treatment Landscape & Competitive Intelligence

Migraine with aura (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Migraine with aura, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Zavzpret zavegepant Pfizer CGRP receptor antagonist Calcitonin gene-related peptide (CGRP) receptor 2023-01-01
Zavzpret Zavegepant Hydrochloride Pfizer Calcitonin Gene-related Peptide Receptor Antagonist Calcitonin gene-related peptide type 1 receptor 2023-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 2 drugs in Migraine with aura

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Migraine with aura:

Cite this brief

Drug Landscape (2026). Migraine with aura — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/migraine-with-aura. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing